PFE

Pfizer, Inc.Healthcare / Drug Manufacturers - GeneralINTACT

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Share Price
$27.56
52W: $23.58 - $29.21
DCF Fair Value
$50.42
+45.3% MoS
P/E (TTM)
36.3x
ROIC
20.9%
Operating Margin
27.9%
FCF Yield
7.9%
Debt / Equity
0.74x
Piotroski Score
9/9
Altman Z-Score
3.16
Market Cap
$157.1B

Price vs. Intrinsic Value Corridor

Margin of Safety Buy Zone (<25% Discount)

Historical market price overlaid against conservative DCF Fair Value & Benjamin Graham Margin of Safety bands.

Period Return (1Y)
()
Period Range
$ - $
DCF Fair Value
$50.42
MOS Buy Target (-25%)
$37.82
Valuation Overlays:

2-Stage Discounted Cash Flow (DCF) Workbench

Conservative intrinsic value model based on owner cash generation over a 10-year investment horizon. Opens with LocalAlpha's baseline assumptions (matching the fair value shown above) — adjust any input to stress-test.

Current Market Price
$27.56
DCF Fair Value
$50.34
+45.2% MoS
$12,486M
$100M$12,486M (Reported)$50,000M
13.9%
-5%10% (Target)35%
4.5%
0%5%20%
9.0%
6%9% (Standard)15% (High Risk)
2.5%
1% (GDP Floor)2.5% (Inflation)4.0%
$51,800M
-$100B CashBalance Sheet+$150B Debt
10-Yr PV of Cash Flows
$140.0B
PV of Terminal Value
$198.7B
Implied Enterprise Value
$338.7B
Implied Equity Value
$286.9B
YearYr 1Yr 2Yr 3Yr 4Yr 5Yr 6Yr 7Yr 8Yr 9Yr 10
Projected FCF ($M)$14,222$16,198$18,450$21,014$23,935$25,013$26,138$27,314$28,543$29,828
Present Value (PV)$13,047$13,634$14,247$14,887$15,556$14,914$14,298$13,708$13,142$12,600

Benjamin Graham & Buffett Value Models

Classical deep value metrics based on asset backing, normalized earnings power, and owner cash yield.

Graham Number-72.4% Premium
$15.99

Calculated as √(22.5 × EPS × BVPS). The maximum theoretical price a defensive investor should pay based purely on asset book value and current earnings.

EPS: $0.76BVPS: $14.95
Revised Graham Formula-34.6% Premium
$20.48

Formula: V = (EPS × (8.5 + 2g) × 4.4) / Y where g is the conservative 7-10 yr growth rate and Y is AAA Bond Yield.

Buffett Owner Earnings7.5% Yield
$2.08 / share

True distributable cash flow: Net Income + D&A - Maintenance CapEx. Reflects the cash Buffett would extract without hurting unit volume.

Total: $11.9BYield: 7.5%

Reverse DCF: Market Growth Expectation

EXTREMELY LOW BARRIER
-0.5% CAGR (Next 10 Yrs)

At the current price of $27.56, the market is assuming the business will compound Free Cash Flow at -0.5% per year for the next decade with a 9% hurdle rate.

Value Investor Verdict
✓ Low market hurdle: Easy for a wide-moat compounder to beat.
Autonomous Thesis Underwriting

Surveil PFE with Mathematical Margin of Safety Rules

Set non-negotiable floor rules for Pfizer, Inc.. If a newly filed quarterly 10-Q breaks your ROIC floor, operating margin boundary, or balance sheet leverage rules, receive an autonomous breach audit within 15 minutes.

Buffett Quality

ROIC > 15% • Margin > 15% • D/E < 0.5x

Margin Floor Guard

Current Margin 27.9% • Floor > 10%

Solvency Guard

Altman-Z > 2.6 • Current Ratio > 1.5x

Frequently Asked Questions: Pfizer, Inc. (PFE) Intrinsic Valuation

Audited fundamentals, DCF intrinsic value sensitivity, and thesis break detection parameters for Pfizer, Inc..

Based on institutional multi-stage Discounted Cash Flow (DCF) modeling on audited SEC cash flows, Pfizer, Inc. has an estimated DCF intrinsic fair value of $50.42 per share compared to its current market price of $27.56. This represents an estimated 45.3% margin of safety (trading below fair value). Additionally, its classic Benjamin Graham Number stands at $15.99.

Related Healthcare Value Stocks & Sector Peers

Compare Pfizer, Inc. with audited intrinsic valuation models across the Healthcare sector.

View All S&P 500 Stocks